3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma, Large B-Cell, Diffuse
14
Lymphoma, Non-Hodgkin
7
Lymphoma, B-Cell
5
Lymphoma
3
Recurrence
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Hodgkin Disease
2
Burkitt Lymphoma
2
Neoplasms
1
Lymphoma, Mantle-Cell
1
Leukemia, Hairy Cell
1
Hematologic Neoplasms
1
Interventions
Cyclophosphamide
15
fludarabine
12
Mycophenolic Acid
10
Standard of Care
9
venetoclax
7
Whole-Body Irradiation
7
Tacrolimus
7
Specimen Handling
7
Sirolimus
6
Practice Guidelines as Topic
6
trametinib
5
Melphalan
5
Azacitidine
5
fludarabine phosphate
4
Mesna
4
Magnetic Resonance Spectroscopy
4
Filgrastim
4
Biopsy
4
Behavior Therapy
4
Thiotepa
3
Radiosurgery
3
Peripheral Blood Stem Cell Transplantation
3
Interviews as Topic
3
GSK2636771
3
Educational Status
3
Cytarabine
3
Crizotinib
3
Busulfan
3
thymoglobulin
2
talquetamab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
polatuzumab vedotin
×
90 days
×
Clear all
NCT04844866
2026-04-29
DALY 2-EU
Miltenyi Biomedicine GmbH
Phase 2
Recruiting
213 enrolled